Drug class
Antiviral prodrug; influenza virus cap-dependent endonuclease inhibitor precursor
Mechanism of action
Baloxavir marboxil is converted to baloxavir acid, which inhibits the cap-dependent endonuclease of the influenza virus polymerase acidic (PA) protein, preventing viral mRNA synthesis and replication.
General use cases
- Treatment of acute uncomplicated influenza in patients aged 5 years and older who are otherwise healthy or at high risk of influenza complications under the US label
- Post-exposure prophylaxis of influenza in eligible patients aged 5 years and older; product- and jurisdiction-specific
For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.
